Speaking & Writing
Puru publishes The RX Signal, a biopharma competitive intelligence publication — game theory underneath, plain English on top. He's also contributed industry analysis and commentary through Fierce Biotech, BioSpace, Evaluate, Citeline, PharmaVoice, GEN, MM+M, and Investor's Business Daily.
Latest from The RX Signal
Vaxcyte's OPUS-1 hits: VAX-31 takes all 28 serotypes
Phase 3 immunogenicity clean sweep in adults 50+ — a genuine competitive threat to the big PCV franchises. Signal 4 · Bark 4 · Oct 5, 2026
Read on The RX Signal →BridgeBio's cardiac bonus: BBP-418 moves the heart, not just the muscle
New exploratory cardiac data strengthens the beat on the November 27 PDUFA countdown. Signal 4 · Bark 4 · Oct 5, 2026
Read on The RX Signal →340B's rebate era is back
What the return of rebate-era dynamics means for manufacturers, covered entities, and the 340B contract pharmacy fight. Signal 4 · Bark 4 · Oct 2, 2026
Read on The RX Signal →Novartis pays $575M upfront for Abogen's in vivo T-cell engager
Dissecting the deal structure — and what it signals about the in vivo cell-therapy race. Signal 4 · Bark 5 · Oct 2, 2026
Read on The RX Signal →Camzyos becomes the first FDA-stamped therapy for kids
A landmark label expansion — and what it means for the obstructive HCM market. Signal 5 · Bark 5 · Oct 1, 2026
Read on The RX Signal →The Combo Meal: why pharma is shifting toward platform deals
The $44 billion question behind pharma's platform-deal hunger. Signal 4 · Bark 4 · Oct 1, 2026
Read on The RX Signal →Career strategy & mentoring
Puru offers one-on-one career strategy and mentoring for biopharma professionals — from single diagnostic sessions to a full acceleration series. If you're navigating the industry and want a straight-talking guide who's sat on both sides of the table: